Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Reports Positive Bevacizumab Results

Avastin Rival Is Firm’s Second Biosimilar With Positive Phase III Outcome

Executive Summary

China’s Bio-Thera Solutions has reported positive Phase III results for its proposed bevacizumab biosimilar rival to Avastin.

You may also be interested in...



Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date

China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.

Biomm Backs Bio-Thera’s Brazilian Bevacizumab

China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.

Related Content

Topics

UsernamePublicRestriction

Register

GB149602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel